# Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

> **NCT03694834** · EARLY_PHASE1 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Endometrial Cancer
- Uterine Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Hysterectomy

## Key facts

- **NCT ID:** NCT03694834
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-29
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694834, "Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03694834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*